TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

Teva Pharmaceutical Industries (TEVA) shares appreciated 21.6% over the past three months, driven by robust sales growth from new branded drugs such as Austedo and Ajovy, coupled with a strengthening pipeline of biosimilars and complex generics, targeting a doubling of biosimilar sales by 2027. This positive momentum is further supported by significant cost-cutting, debt reduction, and pipeline advancements, leading to improved investor sentiment and credit outlook upgrades, despite the company's year-to-date underperformance and anticipated future patent cliffs.

Analysis

Teva Pharmaceutical's stock has appreciated 21.6% in the last three months, signaling a positive shift in investor sentiment driven by a multi-faceted turnaround strategy. Growth is underpinned by its new branded drugs, with Austedo targeting over $2.5 billion in annual revenue by 2027 and Uzedy expected to reach approximately $160 million in 2025 sales. This is complemented by an aggressive expansion in its generics and biosimilars business, which saw 15% growth in the U.S. in 2024 and aims to double global biosimilar sales by 2027 through a pipeline of key launches. Operationally, the company is focused on cost reduction with a goal of achieving a 30% adjusted operating margin by 2027, and its improved financial outlook is validated by recent credit outlook upgrades from Fitch, Moody's, and S&P. However, significant risks persist, including a looming 2026 revenue cliff for its generic lenalidomide and potential headwinds for Austedo from IRA Medicare negotiations in 2027. The stock's valuation presents a mixed picture; while its forward P/E of 6.30 is below the industry average of 10.17, it trades above its 5-year mean, indicating that some of the recovery is already priced in.

Key Decisions for Investors

• Investors should weigh Teva's strong growth catalysts from its branded franchise and robust biosimilar pipeline against clearly defined future risks, including the 2026 lenalidomide patent cliff and potential 2027 IRA impact on Austedo.
• While the stock's forward P/E appears attractive relative to the industry, its premium over its five-year historical average suggests the market is pricing in the turnaround, warranting careful entry point consideration for new capital.
• Closely monitor execution on the biosimilar strategy, particularly the launch of seven U.S. and four European products by 2027, as success is critical to offsetting future revenue gaps and achieving the company's 30% operating margin target.